Search results for: Custom Human 2B4 ELISA ELISA
Error loading info... Pleas try again later.
#18473486 2008/05/13 To Up
Quantification of low-picomolar concentrations of TNF-alpha in serum using the dual-network microfluidic ELISA platform.
For both research and diagnostic purposes, the ability to detect low levels of proteins in a cost- and time-effective manner is essential. In this study, the cytokine TNF-alpha (tumor necrosis factor-alpha), a widely used protein indicator of inflammatory response, was chosen to demonstrate the ability of the dual-network microfluidic ELISA (enzyme-linked immunosorbent assay) platform developed by the authors to rapidly quantify low concentrations of this biomarker in serum. Through the optimization of several experimental parameters, the system was shown to meet the requirements for fundamental and applied studies, while also being relevant for challenging clinical applications such as the diagnosis of septic patients. A sensitivity of 45 pg/mL (2.6 pM) in both culture medium and serum, with inter- and intravariations of less than 15%, was attained for the quantification of human TNF-alpha to a concentration of up to 500 pg/mL. The overall time for completion of the assay in eight parallel reactions was less than 1 h.Marc Herrmann, Teodor Veres, Maryam Tabrizian
1786 related Products with: Quantification of low-picomolar concentrations of TNF-alpha in serum using the dual-network microfluidic ELISA platform.
96 wells (1 kit)1 kit(96 Wells)1 kit(96 Wells)100ug Lyophilized1 kit(96 Wells)96T96T1 kit(96 Wells)96T96T96T100ug LyophilizedRelated Pathways
#15917694 // To Up
Secretion of hepatocyte growth factor and vascular endothelial growth factor during uveal melanoma-monocyte in vitro interactions.
Host-tumour interactions in uveal melanoma, and their involvement in the biological events leading to metastasis and eventually mortality, are not well understood. It is known that uveal melanoma disseminates predominantly via a haematogenous route with metastasis developing primarily in the liver. Therefore, cytokines involved in angiogenesis, such as vascular endothelial growth factor (VEGF), and those expressed in large quantities within the liver, such as hepatocyte growth factor (HGF), are of particular interest in uveal melanoma research. This study investigated the levels of HGF and VEGF in monocyte and uveal melanoma-conditioned medium. Five human uveal melanoma cell lines and one monocyte cell line were seeded in six-well plates. After 18 h, melanoma-conditioned medium (MCM) was placed on the monocyte cell line and monocyte-conditioned medium (MoCM) was placed on each uveal melanoma cell line. Tumour cells and monocytes incubated in fresh, as opposed to conditioned, medium after 18 h were used as controls. VEGF and HGF levels were determined by immunoassay prior to media transfer and 6, 12, 24 and 36 h thereafter. Both cytokines showed an upregulation of expression from all cells after incubation in conditioned medium. 28SC incubated in MCM expressed higher levels of the given cytokines than did uveal melanoma cells incubated in MoCM. In addition, each cell line exhibited a distinct pattern of expression, with individual cell lines exhibiting different peak levels of cytokine production at different time points. These results offer insight into the upregulation of VEGF and HGF, which may play a role in tumour-host cell interactions.Jonathan Cools-Lartigue, Jean Claude Marshall, Amanda L Caissie, Vinicius S Saraiva, Miguel N Burnier
2457 related Products with: Secretion of hepatocyte growth factor and vascular endothelial growth factor during uveal melanoma-monocyte in vitro interactions.
96T2ug x 202ug5ug2ug2ug2ug2ug10ug100.00 ugProtein100.00 ugRelated Pathways
#15057037 // To Up
Macrophage-derived soluble factor enhances melanoma inhibitory activity expression by uveal melanoma cells in vitro.
Melanoma inhibitory activity (MIA) is correlated with tumour progression and development of metastatic disease. Melanoma inhibitory activity, secreted by melanoma cells, is known to inhibit tumour cell attachment to the extracellular matrix enhancing their invasive potential. The regulatory pathways that lead to MIA expression have not yet been elucidated. It is well established that tumour cells and macrophages interact through soluble factors, preventing or enhancing tumour growth. The purpose of the present study was to determine whether soluble factor(s) derived from macrophages lead to the up-regulation of MIA production by human uveal melanoma cell lines (HUMCL) and whether MIA contributes to an increase in the invasive behaviour of HUMCL in vitro. Baseline MIA levels were measured by enzyme-linked immunosorbent assay in five HUMCL of known metastatic potential (92.1>SP6.5>OCM-1>MKT-BR>UW-1). Macrophage conditioned medium (MaCM) was placed on top of the HUMCL and MIA levels were measured at 6, 12, 24, and 36 h. The HUMCL were also seeded in a Matrigel chamber for 72 h and then cells invading the Matrigel were counted. The assay was repeated adding recombinant human MIA to the top layer of each well. All HUMCL expressed MIA at baseline (average of 31 ng/ml at 36 h). Following exposure to MaCM, MIA levels increased to an average of 45.2 ng/ml, with the 92.1 and SP6.5 cell lines expressing the highest MIA levels and UW-1 cell line expressing the lowest level. During the baseline invasion assay, the vast majority of cells (>95%) were found to adhere to the upper surface of the Matrigel. When MIA was added to the invasion chamber, no adhesion or invasion was observed. The results suggest, for the first time, that macrophages secrete a soluble factor(s) that may stimulate nearby melanoma cells to enhance their production of MIA in vitro. Furthermore, increased MIA production may, in turn, increase the invasive properties of the cells by modulating the attachment of HUMCL to the extracellular matrix.Sonia A Callejo, Jean-Claude Marshall, Jonathan Cools-Lartigue, Vinicius S Saraiva, Miguel N Burnier
1915 related Products with: Macrophage-derived soluble factor enhances melanoma inhibitory activity expression by uveal melanoma cells in vitro.
10 ug1 mg10 5Related Pathways
Error loading info... Pleas try again later.
Contact Us:
Belgium
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
[email protected]
France
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
[email protected]
Germany
GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
[email protected]
United Kingdom
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
[email protected]
Also in
Luxembourg +35220880274
Schweiz Züri +41435006251
Danmark +4569918806
Österreich +43720880899
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
Poland
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
[email protected]
skype gentaurpoland
Nederland
GENTAUR Nederland BV
Kuiper 1
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
[email protected]
Italy
GENTAUR SRL
IVA IT03841300167
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
[email protected]
Spain
GENTAUR Spain
Tel 0911876558
[email protected]
Bulgaria
GENTAUR Bulgaria
53 Iskar Str. 1191 Kokalyane, Sofia
Sofia 1000
Tel 0035924682280
Fax 0035929830072
[email protected]